Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

Clinical Pharmacokinetics

Volumn 42, Issue 4, 2003, Pages 381-392

  Johansson, Linda C ^a   Frison, Lars ^a   Logren, Ulrika ^a   Fager, Gunnar ^a   Gustafsson, David ^a   Eriksson, Ulf G ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBIN; XIMELAGATRAN;

ADULT; AGE; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG TRANSFORMATION; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; KIDNEY FUNCTION; NORMAL HUMAN; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AREA UNDER CURVE; AZETIDINES; BENZYLAMINES; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; FIBRINOLYTIC AGENTS; FOOD-DRUG INTERACTIONS; GLYCINE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PRODRUGS; THROMBIN;

EID: 0037256123     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342040-00006     Document Type: Article

References (27)

1. Tavazzi L. Clinical epidemiology of acute myocardial infarction. Am Heart J 1999 Aug; 138 (2 Pt 2): S48-54
2. Tegos TJ, Kalodiki E, Daskalopoulou SS, et al. Stroke: epidemiology, clinical picture, and risk factors: part I of III. Angiology 2000; 51: 793-808
3. Williams GR, Jiang JG, Matchar DB, et al. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke 1999; 30: 2523-8
4. Nordström M, Lindblad B, Bergqvist D, et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60
5. Anderson Jr FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-8
6. Weitz JI, Hirsh J. New anticoagulant drugs. Chest 2001; 119 (1 Suppl.): 95S-107S
7. Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78: 1286-92
8. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999; 94: 187-97
9. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 110-8
10. Mehta JL, Chen L, Nichols WW, et al. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 1998; 31: 345-51
11. Eriksson BI, Carlsson S, Halvarsson M, et al. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular-weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 1997; 78: 1404-7
12. Mattsson C, Björkman JA, Ulvinge JC. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis. Fibrinolysis Proteolysis 1997; 11: 121-8
13. Eriksson BI, Bergqvist D, Kälebo P, et al. The oral, direct thrombin inhibitor, ximelagatran, and its active form, melagatran, in ascending doses compared with dalteparin for prevention of venous thromboembolism after total hip or total knee replacement: The METHRO II study. Lancet 2002; 360: 1441-7
14. Eriksson H, Eriksson UG, Frison L, et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999; 81: 358-63
15. Eriksson H, Wåhlander K, Gustafsson D, et al. A randomised, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003: 1: 41-7
16. Petersen P. SPORTIF II Investigators. Long-term treatment of patients using the new oral direct thrombin inhibitor ximelagatran (pINN, formerly H 376/95) versus warfarin in moderate to high stroke risk patients with atrial fibrillation. J Neurol Sci 2001; 187 Suppl. 1: S124-5
17. Eriksson UG, Bredberg U, Hoffmann K-J, et al. Absorption, distribution, metabolism and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003; 31: 294-305
18. Gustafssson D, Nystrom J, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81
19. Eriksson UG, Bredberg U, Gislén K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol. In press
20. Hämmerlein A, Derendorf H, Lowenthal D. Pharmacokinetics and pharmacodynamics changes in the elderly: clinical implications. Clin Pharmacokinet 1998; 35: 49-64
21. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 1999; 45: 243-53
22. Rainfray M, Richard-Harston S, Salles-Montaudon N, et al. Effects of aging on kidney function and implications for medical practice. Presse Med 2000; 29: 1373-8
23. Schenker S, Bay M. Drug disposition and hepatotoxicity in the elderly. J Clin Gastroenterol 1994; 18: 232-7
24. Marchant B. Pharmacokinetic factors influencing variability in human drug response. Scand J Rheumatol Suppl 1981; 39: 5-14
25. Larsson M, Logren U, Ahnoff M, et al. Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography: mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766: 47-55
26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
27. Mattsson C, Menschiek-Lundin A, Wåhlander K, et al. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thromb Haemost 2001: 86: 611-5